Needle-Free Injection Systems Market

Needle-Free Injection Systems Market by Product (Fillable, Prefilled), by Technology (Jet-Based, Spring-Based, Laser-Powered, Vibration-Based), by Type (Liquid-Based, Projectile/Depot-Based, Powder-Based), by Usability (Disposable, Reusable), by Site of Delivery (Intramuscular, Subcutaneous, Intradermal), by Application (Oncology, Insulin Delivery, Vaccine Delivery, Pain Management), by End User (Hospitals and Clinics, Home Care Settings), by Geography (U.S., Canada, Germany, France, U.K., Italy, Spain, China, Japan, India, Brazil, Mexico) – Global Market Size, Share, Development, Growth, and Demand Forecast, 2013–2023

Delivery : 24-72 Working Hours
Report Code: LS11347
Available Format:

Needle-Free Injection Systems Market Overview

The global needle-free injection systems market will experience extensive growth in the coming years due to the rising demand for self-injection devices and emerging biological therapies. The vendors of these systems offer fillable and prefilled needle-free injectors in the market, of which prefilled needle-free injectors constitute the larger share. The increasing demand for low-cost self-injection devices by patients and healthcare providers and rising focus on compliance with needle safety regulations to avoid needlestick injuries are some of the factors that have led to an increase in the use of prefilled needle-free injectors.

Different technologies such as jet-based, spring-based, laser-powered, and vibration-based are used in needle-free injectors to ensure smoother drug delivery process. Among these technologically advanced needle-free injection systems, jet-based needle-free injectors held the largest share in 2016, due to their advantages over other injectors. The needle-free injection systems market can further be classified according to their type as liquid-based needle-free injectors, projectile/depot-based needle-free injectors, and powder-based needle-free injectors. With rising prevalence of diabetes, the market for liquid-based needle-free injectors is expected to generate the largest revenue during the forecast period.

Needle-free injection systems are generally penetrated via intramuscular, subcutaneous, and intradermal routes. These injectors find their application in oncology, insulin delivery, vaccine delivery, pain management, and others. Needle-free injectors finds largest application in vaccine delivery, mainly because of the increasing prevalence of chronic diseases. Insulin delivery application has also witnessed significant growth with the use of needle-free injection systems by the increasing patient base suffering from diabetes.

The key end-user in the needle-free injection systems market are hospitals and clinics, home care settings, and others including research laboratories, and pharmaceutical and biotechnology companies. Hospitals and clinics are expected to register the largest share during the forecast period, with home care settings projected to grow at the fastest rate because of increasing demand for self-injection devices and growing aging population.

Needle-Free Injection Systems Market Dynamics

Growth Drivers and Restraints

Most of the biologics, such as monoclonal antibodies, anticoagulants, and vaccines, are large molecules that need to be administered parenterally to achieve the desired therapeutic effects. The demand for injectable biologic therapies is increasing, since many peptides break down quickly in the stomach, no longer remaining useful for the treatment. Also, various biologic drugs and vaccines are required to be injected directly into the bloodstream. Additionally, the introduction of biosimilars is expected to increase the use of injectables for self-administration; hence, emerging biologic therapies are expected to fuel the growth of the needle-free injection systems market.

However, high cost of technologically advanced needle-free injection systems and stringent regulations associated with such devices are hampering the growth of the needle-free injection systems industry. Also, self-administered drug delivery devices demand adequate knowledge on their proper and correct usage to avoid cases of needlestick injuries. Because of the lack of knowledge on their usage, adherence to needle-free injection systems is less in developing countries as compared to developed countries like the U.S. and Europe.

Opportunities and Trends

The increasing demand and penetration of needle-free injection systems in emerging economies offer enormous growth opportunities to the players in the needle-free injection systems industry. Since needle-free injection systems make the whole process of self-administration of drugs quite easy and convenient for the patients, transition from hospital care to home care settings has been seen in recent years. The shifting interest of consumers from hospital to home for their healthcare needs has been a key trend observed in the needle-free injection systems market.

Needle-Free Injection Systems Market Insights by Geography

North America holds the largest share in the global needle-free injection systems market because of increasing prevalence of chronic diseases, improved healthcare infrastructure, and rising geriatric population. Europe is expected to register the fastest growth because of increasing prevalence of diabetes and other chronic diseases, and government initiatives to provide better healthcare facilities. The various initiatives taken by the European Commission to improve the healthcare system in the region would also foster the growth of the auto-injectors market. The European Commission, with its program named Horizon 2020 (2014–2020), plans to invest $8.82 billion (EUR7.5 billion) in research to improve the European healthcare system.

Needle-Free Injection Systems Market Competitive Landscape

Some of the key players in the needle-free injection systems industry include Endo International PLC, Antares Pharma Inc., Medical International Technology Inc., PharmaJet, Bioject Medical Technologies Inc., National Medical Products Inc., INJEX Pharma AG, Valeritas Holdings Inc., Crossject SA, PenJet Corporation, and European Pharma Group.
With respect to strategic developments, various new product launches and approvals have been taken in the needle-free injection systems market.

In March 2017, PharmaJet announced its partnership with Serum Institute of India to commercialize needle-free delivery of the measles, mumps, and rubella (MMR) vaccine using the Stratis 0.5 mL needle-free injection system.

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry